An Open-label, Phase 1 Dose Escalation Study of Oral ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2019
Price : $35 *
At a glance
- Drugs Naquotinib (Primary) ; Midazolam
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Astellas Pharma Global Development
- 28 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019.
- 27 Sep 2017 Final results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
- 10 May 2017 Status changed from active, no longer recruiting to discontinued, as reported in an Astellas Pharma media release.